This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stephens, B. J. Articles by Von Hoff, D. D. Search for Related Content PubMed PubMed Citation Articles by Stephens, B. J. Articles by Von Hoff, D. D. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Minireview

PRL phosphatases as potential molecular targets in cancer

Departments of ¹ Molecular and Cellular Biology and ² Pharmacology and Toxicology, University of Arizona, Tucson, Arizona and ³ Translational Genomics Research Institute, Phoenix, Arizona

Requests for reprints: Daniel D. Von Hoff, Translational Genomics Research Institute, 445 North Fifth Street, Phoenix, AZ 85004. Phone: 602-358-8327; Fax: 602-343-8484. E-mail: dvh{at}tgen.org

The phosphatase of regenerating liver (PRL) family of phosphatases, consisting of PRL-1, PRL-2, and PRL-3, represents an intriguing group of proteins being validated as biomarkers and therapeutic targets in cancer. Individual PRLs are overexpressed in a variety of cancer cell lines and tissues when compared with their normal counterparts. More importantly, several recent studies have shown that PRL-3 is expressed at higher levels and at a greater frequency in colorectal cancer metastases compared with primary colorectal tumors and normal colon tissue. Ectopic expression of PRLs in nontumorigenic cells can influence proliferation and the migratory and invasive properties of cells, while knockdown of endogenous PRL-3 or PRL-1 in cancerous cells using small interfering RNA can abrogate cell motility and ability to metastasize in a mouse model. However, the exact biological function and cellular substrates of the PRLs remain unclear. This review will discuss what is known about the PRLs, what makes the PRLs possible attractive targets for therapeutic intervention, and the possible future directions in PRL biology and inhibitor identification.

This article has been cited by other articles:

				P. Radivojac, P. H. Baenziger, M. G. Kann, M. E. Mort, M. W. Hahn, and S. D. Mooney Gain and loss of phosphorylation sites in human cancer Bioinformatics, August 15, 2008; 24(16): i241 - i247. [Abstract] [Full Text] [PDF]

				F. Liang, Y. Luo, Y. Dong, C. D. Walls, J. Liang, H.-Y. Jiang, J. R. Sanford, R. C. Wek, and Z.-Y. Zhang Translational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase J. Biol. Chem., April 18, 2008; 283(16): 10339 - 10346. [Abstract] [Full Text] [PDF]

				S. Daouti, W.-h. Li, H. Qian, K.-S. Huang, J. Holmgren, W. Levin, L. Reik, D. L. McGady, P. Gillespie, A. Perrotta, et al. A Selective Phosphatase of Regenerating Liver Phosphatase Inhibitor Suppresses Tumor Cell Anchorage-Independent Growth by a Novel Mechanism Involving p130Cas Cleavage Cancer Res., February 15, 2008; 68(4): 1162 - 1169. [Abstract] [Full Text] [PDF]

				U.-M. Fagerli, R. U. Holt, T. Holien, T. K. Vaatsveen, F. Zhan, K. W. Egeberg, B. Barlogie, A. Waage, H. Aarset, H. Y. Dai, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells Blood, January 15, 2008; 111(2): 806 - 815. [Abstract] [Full Text] [PDF]

				B. Stephens, H. Han, G. Hostetter, M. J. Demeure, and D. D. Von Hoff Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells Mol. Cancer Ther., January 1, 2008; 7(1): 202 - 210. [Abstract] [Full Text] [PDF]

				M. S. Lee, L. Johansen, Y. Zhang, A. Wilson, M. Keegan, W. Avery, P. Elliott, A. A. Borisy, and C. T. Keith The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action Cancer Res., December 1, 2007; 67(23): 11359 - 11367. [Abstract] [Full Text] [PDF]

				J.-P. Sun, Y. Luo, X. Yu, W.-Q. Wang, B. Zhou, F. Liang, and Z.-Y. Zhang Phosphatase Activity, Trimerization, and the C-terminal Polybasic Region Are All Required for PRL1-mediated Cell Growth and Migration J. Biol. Chem., September 28, 2007; 282(39): 29043 - 29051. [Abstract] [Full Text] [PDF]

				C. W. Ross, P. D. Ouillette, C. M. Saddler, K. A. Shedden, and S. N. Malek Comprehensive Analysis of Copy Number and Allele Status Identifies Multiple Chromosome Defects Underlying Follicular Lymphoma Pathogenesis Clin. Cancer Res., August 15, 2007; 13(16): 4777 - 4785. [Abstract] [Full Text] [PDF]

				H. Wang, S. Y. Quah, J. M. Dong, E. Manser, J. P. Tang, and Q. Zeng PRL-3 Down-regulates PTEN Expression and Signals through PI3K to Promote Epithelial-Mesenchymal Transition Cancer Res., April 1, 2007; 67(7): 2922 - 2926. [Abstract] [Full Text] [PDF]

				F. Liang, J. Liang, W.-Q. Wang, J.-P. Sun, E. Udho, and Z.-Y. Zhang PRL3 Promotes Cell Invasion and Proliferation by Down-regulation of Csk Leading to Src Activation J. Biol. Chem., February 23, 2007; 282(8): 5413 - 5419. [Abstract] [Full Text] [PDF]

				H. Achiwa and J. S. Lazo PRL-1 Tyrosine Phosphatase Regulates c-Src Levels, Adherence, and Invasion in Human Lung Cancer Cells Cancer Res., January 15, 2007; 67(2): 643 - 650. [Abstract] [Full Text] [PDF]

				T. Kato, S. Hayama, T. Yamabuki, N. Ishikawa, M. Miyamoto, T. Ito, E. Tsuchiya, S. Kondo, Y. Nakamura, and Y. Daigo Increased Expression of Insulin-like Growth Factor-II Messenger RNA-Binding Protein 1 Is Associated with Tumor Progression in Patients with Lung Cancer Clin. Cancer Res., January 15, 2007; 13(2): 434 - 442. [Abstract] [Full Text] [PDF]

				L Wang, L Peng, B Dong, L Kong, L Meng, L Yan, Y Xie, and C Shou Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome Ann. Onc., October 1, 2006; 17(10): 1517 - 1522. [Abstract] [Full Text] [PDF]

				J. J. Fiordalisi, P. J. Keller, and A. D. Cox PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res., March 15, 2006; 66(6): 3153 - 3161. [Abstract] [Full Text] [PDF]